stockrowAstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +22.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
Follow AZN
Alert me
AstraZeneca PLC (AZN) Return on assets
AstraZeneca PLC's return on assets over the twelve months to 30 September 2026 was 9.41%, up 0.0 percentage points from fiscal 2025 (9.38%). Over the past ten years it has ranged from 0.13% (fiscal 2021) to 9.38% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers General industry median of 2.28% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 9.38% | 2.52 |
| FY2024 | 6.86% | 0.83 |
| FY2023 | 6.03% | 2.77 |
| FY2022 | 3.26% | 3.13 |
| FY2021 | 0.13% | (4.86) |
| FY2020 | 4.99% | 2.80 |
| FY2019 | 2.19% | (1.29) |
| FY2018 | 3.48% | (1.29) |
| FY2017 | 4.77% | (0.94) |
| FY2016 | 5.71% | 0.95 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| NVO Novo Nordisk A/S compare | 22.0% |
| AMGN Amgen Inc. compare | 10.1% |
| BMY Bristol Myers Squibb Company compare | 9.96% |
| AZN AstraZeneca PLC | 9.41% |
| NVS Novartis AG compare | 8.94% |
| ABBV AbbVie Inc. compare | 7.32% |
| PFE Pfizer Inc. compare | 1.95% |
| MRK Merck & Co., Inc. compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −7.03% |
| Drug Manufacturers General industry median | 2.28% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on AZN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement